Headline »
Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) For The Treatment Of Fabry Disease
Wed, 24/06/09 – 7:42 | No Comment

Amicus Therapeutics (Nasdaq: FOLD) announced it has commenced the U.S. registration Phase 3 trial with its investigational drug, Amigal(TM) (migalastat hydrochloride) for the treatment of Fabry disease. The Company has reached agreement with the …

Read the full story »
Aim to Cure

A focus on disease-specific efforts by pharmaceutical and biotech companies

Analysis

Read in depth analysis by industry experts on investing opportunities and business strategies

Company Profiles

Learn about corporate strategies, positioning and investing opportunities

Industry News

Stay on top of the industry with our industry news bulletin

Mutual Funds

Diversify to hedge your investment during economic turbulence

Home » Aim to Cure, Analysis, Featured, Headline, Industry News

Unique Collaboration Between TB Alliance And Tibotec To Accelerate Tuberculosis Drug Development

Submitted by Robert Lawrence on Friday, 19 June 2009No Comment

A new landmark collaboration between the Global Alliance for TB Drug Development (TB Alliance), a not-for-profit, product development partnership, and Tibotec Inc., (Tibotec), a global pharmaceutical company, has been announced at the Pacific Health Summit in response to the urgent need to accelerate the discovery and development of new drugs to fight tuberculosis (TB).

Leave a comment!

Add your comment below, or trackback from your own site. You can also subscribe to these comments via RSS.

Be nice. Keep it clean. Stay on topic. No spam.

You can use these tags:
<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

This is a Gravatar-enabled weblog. To get your own globally-recognized-avatar, please register at Gravatar.